Abstract
With its superior sensitivity and specificity, cardiac troponin has gradually replaced other cardiac enzymes, and is now the biomarker of choice in making the critical diagnosis of an acute coronary syndrome (ACS). The early stratification of risk from unstable angina to non-ST segment elevation myocardial infarction (NSTEMI), is crucial in the timing and treatment of the ACS. Troponin elevations have also been shown to be powerfully prognostic in a variety of clinical settings and because of this predictive value, may be useful in determining benefit of various clinical interventions. However, inherent in this improved sensitivity and specificity of the measurement tools is the inclusion of non-ACS patients with abnormal troponin measurements. Increased understanding of the alternative diagnoses associated with elevated troponins as well as assays which allow more rapid and accurate diagnosis of ACS, are needed to further improve patient care. Clinical trials of risk stratification controlling for concomitant associated diagnoses including renal insufficiency, pulmonary embolism, atrial fibrillation and congestive heart failure will provide data to optimize this tool.
Keywords: Troponin, ACS, cardiac biomarkers, chest pain, NSTEMI
Cardiovascular & Hematological Disorders-Drug Targets
Title: Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?
Volume: 8 Issue: 2
Author(s): Lisa S. Rosenbaum and James L. Januzzi
Affiliation:
Keywords: Troponin, ACS, cardiac biomarkers, chest pain, NSTEMI
Abstract: With its superior sensitivity and specificity, cardiac troponin has gradually replaced other cardiac enzymes, and is now the biomarker of choice in making the critical diagnosis of an acute coronary syndrome (ACS). The early stratification of risk from unstable angina to non-ST segment elevation myocardial infarction (NSTEMI), is crucial in the timing and treatment of the ACS. Troponin elevations have also been shown to be powerfully prognostic in a variety of clinical settings and because of this predictive value, may be useful in determining benefit of various clinical interventions. However, inherent in this improved sensitivity and specificity of the measurement tools is the inclusion of non-ACS patients with abnormal troponin measurements. Increased understanding of the alternative diagnoses associated with elevated troponins as well as assays which allow more rapid and accurate diagnosis of ACS, are needed to further improve patient care. Clinical trials of risk stratification controlling for concomitant associated diagnoses including renal insufficiency, pulmonary embolism, atrial fibrillation and congestive heart failure will provide data to optimize this tool.
Export Options
About this article
Cite this article as:
Rosenbaum S. Lisa and Januzzi L. James, Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?, Cardiovascular & Hematological Disorders-Drug Targets 2008; 8 (2) . https://dx.doi.org/10.2174/187152908784533711
DOI https://dx.doi.org/10.2174/187152908784533711 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Osteoprotegerin in Cardiovascular Disease: Ally or Enemy?
Current Pharmaceutical Design Editorial (Thematic Issue: Targeting Inflammation in Cardiovascular Disease)
Medicinal Chemistry Radiological Screening Programs for Women at High Risk of Developing Breast Cancer
Current Women`s Health Reviews Evolving Concepts Concerning Cardiac β-Adrenoceptor Function in Heart Failure
Current Pharmaceutical Design Hypereosinophilic Syndrome, Churg-Strauss Syndrome and Parasitic Diseases: Possible Links between Eosinophilia and Thrombosis
Current Vascular Pharmacology Preservation Solutions for Solid Organ Transplantation
Mini-Reviews in Medicinal Chemistry Analytical Techniques for the Estimation of Perindopril Erbumine: A Review
Current Pharmaceutical Analysis Interrelationship between Chronic Kidney Disease and Risk of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry It’s Time for An Epigenomics Roadmap of Heart Failure
Current Genomics Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives
Current Stem Cell Research & Therapy Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design Editorial (Thematic Issue: Treating Major Age-Related Diseases in Older and Oldest Old Patients)
Current Pharmaceutical Design Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
Current Topics in Medicinal Chemistry Metallothioneins, Ageing and Cellular Senescence: A Future Therapeutic Target
Current Pharmaceutical Design Itraconazole Induced Congestive Heart Failure, A Case Study
Current Drug Safety Phosphatidylinositol 3-kinase Signaling as a Therapeutic Target for Cervical Cancer
Current Cancer Drug Targets Statins and Vulnerable Plaque
Current Pharmaceutical Design Polyphenols and Aging
Current Aging Science